Bellerophon Therapeutics (BLPH) Earns Daily Coverage Optimism Rating of 0.09

News articles about Bellerophon Therapeutics (NASDAQ:BLPH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bellerophon Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.3361090333971 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several brokerages have issued reports on BLPH. ValuEngine upgraded shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Monday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.

Bellerophon Therapeutics (NASDAQ:BLPH) traded down $0.17 during trading hours on Thursday, reaching $1.38. The company had a trading volume of 225,200 shares, compared to its average volume of 740,837. Bellerophon Therapeutics has a twelve month low of $0.43 and a twelve month high of $1.98.

WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply